- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Nordea Investment Management AB Boosts Stake in Illumina
Institutional investor increases holding in life sciences company by over 2,700%
Mar. 23, 2026 at 9:48am
Got story updates? Submit your updates here. ›
Nordea Investment Management AB significantly increased its stake in Illumina, Inc. (NASDAQ:ILMN) during the fourth quarter, growing its position by 2,792.2% to 944,500 shares worth approximately $124.15 million. The fund now owns around 0.62% of the life sciences company's stock.
Why it matters
Illumina is a leading provider of DNA sequencing systems and related products, playing a crucial role in the field of genomics research and clinical diagnostics. Nordea's substantial investment in the company signals the fund's confidence in Illumina's long-term growth potential and the continued importance of genomics technology.
The details
According to a recent SEC filing, Nordea Investment Management AB acquired an additional 911,843 shares of Illumina during the fourth quarter, bringing its total holding to 944,500 shares. This represents a 2,792.2% increase in the fund's position compared to the prior quarter. Nordea now owns approximately 0.62% of Illumina's outstanding shares, valued at around $124.15 million as of the most recent filing.
- Nordea increased its Illumina stake during the fourth quarter of 2025.
The players
Nordea Investment Management AB
A major European asset management firm that has significantly increased its stake in Illumina, a leading life sciences company.
Illumina, Inc.
A global life sciences company that develops and markets integrated systems for genetic analysis and functions, playing a crucial role in the field of genomics research and clinical diagnostics.
The takeaway
Nordea's substantial investment in Illumina underscores the growing importance of genomics technology and the life sciences company's position as a leader in the field. This move signals the fund's long-term confidence in Illumina's growth potential and the continued relevance of genomics research and applications.
